Literature DB >> 27823604

Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.

Fernando Bril1, Kenneth Cusi2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is increasingly common in patients with type 2 diabetes mellitus (T2DM), with an estimated prevalence of 60% to 80%. The relationship of NAFLD and T2DM is complex, with each condition negatively affecting the other. Although NAFLD is associated with more metabolic and cardiovascular complications and worse hyperglycemia, T2DM accelerates the progression of liver disease in NAFLD. Despite the high prevalence and serious clinical implications, NAFLD is usually overlooked in clinical practice. This article focuses on understanding the relationship between NAFLD and T2DM, to provide better care for these complex patients.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes; Insulin resistance; Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Obesity; Pioglitazone; Thiazolidinediones

Mesh:

Year:  2016        PMID: 27823604     DOI: 10.1016/j.ecl.2016.06.005

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  34 in total

Review 1.  Diabetes Mellitus and the Colon.

Authors:  Marc S Piper; Richard J Saad
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

2.  Non-alcoholic fatty liver disease.

Authors:  Wenhao Li; William Alazawi
Journal:  Clin Med (Lond)       Date:  2020-09       Impact factor: 2.659

3.  HDL flux is higher in patients with nonalcoholic fatty liver disease.

Authors:  Arthur McCullough; Stephen F Previs; Jaividhya Dasarathy; Kwangwon Lee; Abdullah Osme; Chunki Kim; Serguei Ilchenko; Shuhui W Lorkowski; Jonathan D Smith; Srinivasan Dasarathy; Takhar Kasumov
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-09-10       Impact factor: 4.310

Review 4.  A Fad too Far? Dietary Strategies for the Prevention and Treatment of NAFLD.

Authors:  Mary P Moore; Rory P Cunningham; Ryan J Dashek; Justine M Mucinski; R Scott Rector
Journal:  Obesity (Silver Spring)       Date:  2020-09-06       Impact factor: 5.002

5.  Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.

Authors:  Jeff Y Yang; Andrew M Moon; Hannah Kim; Virginia Pate; A Sidney Barritt; Matthew J Crowley; John B Buse; Til Stürmer; Anastasia-Stefania Alexopoulos
Journal:  J Diabetes Complications       Date:  2020-08-05       Impact factor: 2.852

6.  Effect of vitamin D3 supplementation on hepatic lipid dysregulation associated with autophagy regulatory AMPK/Akt-mTOR signaling in type 2 diabetic mice.

Authors:  Hyewon Lim; Heaji Lee; Yunsook Lim
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-04

7.  Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis.

Authors:  Srilaxmi Kalavalapalli; Fernando Bril; Jeremy P Koelmel; Kaitlyn Abdo; Joy Guingab; Paige Andrews; Wen-Yi Li; Dhanya Jose; Richard A Yost; Reginald F Frye; Timothy J Garrett; Kenneth Cusi; Nishanth E Sunny
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-04-10       Impact factor: 4.310

Review 8.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 9.  Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors.

Authors:  Oriol Juanola; Sebastián Martínez-López; Rubén Francés; Isabel Gómez-Hurtado
Journal:  Int J Environ Res Public Health       Date:  2021-05-14       Impact factor: 3.390

10.  High-Normal Serum Thyrotropin Levels Increased the Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects with Type 2 Diabetes.

Authors:  Ying Tan; Xixiang Tang; Panwei Mu; Yi Yang; Mei Li; Yuanpeng Nie; Haicheng Li; Yanhua Zhu; Yanming Chen
Journal:  Diabetes Metab Syndr Obes       Date:  2021-06-22       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.